Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Get Alerts APLS Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following investor conferences:
- 5th Annual Evercore ISI HealthCONx Conference: Fireside chat on Tuesday, November 29, 2022, at 8:25 a.m. ET.
- Bank of America 2022 Virtual Biotech SMID Cap Conference: Fireside chat on Wednesday, December 7, 2022, at 9:40 a.m. ET.
Each conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
[email protected]
617.599.8178
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Steelworkers back Canada holding the line on trade, call for a stronger response to protect Canadian jobs and industry
- Watershed Roofing Inc. Expands Roofing and Exterior Services Across British Columbia
- Polygon Joins Digital Pound Lab as XRP Rallies, Best Altcoin To Buy Now AlphaPepe Builds Toward Launch
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, BofA/Merrill LynchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share